Kobayashi Pharmaceutical Announces Results for the Third Quarter Ended December 31, 2005.Tokyo, Japan, Jan 23, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) Newswire) - Kobayashi Pharmaceutical, Ltd. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4967), a leading importer and distributor of medical equipment and pharmaceutical and consumer goods consumer goods Any tangible commodity purchased by households to satisfy their wants and needs. Consumer goods may be durable or nondurable. Durable goods (e.g., autos, furniture, and appliances) have a significant life span, often defined as three years or more, and wholesaler, today announced consolidated financial results for the third quarter ended December 31, 2005. Net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight and operating, ordinary and net income all demonstrated strong improvement on the previous year. Expanded investments in plants and equipment as a result of improved corporate earnings, a rally in consumer spending Consumer demand or consumption is also known as personal consumption expenditure. It is the largest part of aggregate demand or effective demand at the macroeconomic level. , and other factors indicated that Japan's economy in the third quarter had broken out of stagnation Stagnation A period of little or no growth in the economy. Economic growth of less than 2-3% is considered stagnation. Sometimes used to describe low trading volume or inactive trading in securities. Notes: A good example of stagnation was the U.S. economy in the 1970s. and embarked on a slow recovery trend, but prospects surrounding increasing crude oil prices and the future U.S. economy remain uncertain. Throughout the term, Kobayashi sought to cultivate cul·ti·vate tr.v. cul·ti·vat·ed, cul·ti·vat·ing, cul·ti·vates 1. a. To improve and prepare (land), as by plowing or fertilizing, for raising crops; till. b. and reinforce the spirit of the Group concept of "creation and innovation, and development of customer needs by providing products and services to create new markets while striving for fresh added value Added value in financial analysis of shares is to be distinguished from value added. Used as a measure of shareholder value, calculated using the formula:
As a result, net sales amounted to 192,315 million yen, an increase of 16.6% from the previous fiscal year, operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. was 14,251 million yen, an increase of 8.4% from the previous year. Ordinary income was 13,225 million yen, an increase of 9.1% from the previous year, and net income for the quarter was 6,939 million yen, an increase of 10.8% from the previous year. Consolidated Financial Summary (April 1, 2005 - September 30, 2005) (1) Consolidated Operating Results
------------------------------------------------------------------------
(Millions of Yen)
April 1 - Dec. 31, FY 3/31,
2005 % 2004 % 2005
------------------------------------------------------------------------
Operating Revenues 192,315 16.6 165,003 (1.1) 215,708
Operating Income 14,251 8.4 13,141 (6.1) 15,698
Ordinary Income 13,225 9.1 12,121 (3.7) 14,159
Net Income 6,939 10.8 6,264 11.6 6,730
Net Income per Share (yen) 166.96 150.51 160.64
Net Income per Share,
diluted (yen) 166.91 -- --
------------------------------------------------------------------------
(2) Consolidated Financial Position
------------------------------------------------------------------------
(Millions of Yen)
As of December 31, As of March 31,
2005 2004 2005
------------------------------------------------------------------------
Total Assets 161,353 139,205 134,629
Shareholders' Equity 65.533 59,572 60,116
Shareholders' Equity Ratio 40.6% 42.8% 44.7%
Shareholders' Equity
per Share (Yen) 1,587.87 1,431.26 1,443.30
------------------------------------------------------------------------
(3) Consolidated Cash Flows
------------------------------------------------------------------------
(Millions of Yen)
As of December 31, As of March 31,
2004 2003 2005
------------------------------------------------------------------------
Cash Flows from
Operating Activities 9,705 6,695 8,364
Cash Flows from
Investing Activities (4,940) (2,411) (3,936)
Cash Flows from
Financing Activities (923) (3,510) (3,369)
Cash and Cash Equivalents,
End of term 22,950 18,702 19,035
------------------------------------------------------------------------
Summary of Performance by Business Segment Consumer Products Operation This operation saw the development of existing brands such as "Shoshu Gen" aromatic aromatic /ar·o·mat·ic/ (ar?o-mat´ik) 1. having a spicy odor. 2. in chemistry, denoting a compound containing a ring system stabilized by a closed circle of conjugated double bonds or nonbonding electron pairs, e.g. deoderizer, "Inochi-no-Haha" feminine health care medicine which went on the market in June, "Eyebon Trolly trol·ly n. & v. Variant of trolley. Eye Lotion lotion /lo·tion/ (lo´shun) a liquid suspension, solution, or emulsion for external application to the body. lo·tion n. 1. Dry Eye" launched in the fall, and "Mukumi Cure" massage massage (məsäzh`), treatment of superficial parts of the body by systematic rubbing, stroking, kneading, or slapping. Massages can be administered manually or with mechanical devices. socks, which contributed to sales growth. In addition, as a result of an increase in "Kairo" (disposable heating pad) sales due to record winter temperatures, sales of the Consumer Product Operation increased 4,601 million yen, or 6.5%, from the previous year to 75,149 million yen. On the other hand, the operating income increased 1,004 million yen, or 8.1%, from the previous year to 13,441 million yen owing to owing to prep. Because of; on account of: I couldn't attend, owing to illness. owing to prep → debido a, por causa de the execution of the cost reduction in the cost of goods manufactured etc. in addition to the sales extension. Wholesale Operation Following the transfer on April 1 of Suzuken's general pharmaceutical wholesaling business, this segment's sales rose by 22,323 million yen, 22.4% over the previous year, to 121,879 million yen. But the effects of the integration by acquiring business were not fully reflected in operating results, and the operating income was 240 million yen, a decline of 180 million yen, or 42.8 % compared to the previous year. Medical Devices Operation In the domestic market, emphasis was placed on the orthopedic surgery Orthopedic Surgery Definition Orthopedic (sometimes spelled orthopaedic) surgery is surgery performed by a medical specialist, such as an orthopedist or orthopedic surgeon, trained to deal with problems that develop in the bones, joints, and ligaments domain with its prospects for market expansion, and in sales of surgical products such as electric scalpels, and sales tended strongly. On the other hand, indirect costs Indirect costs are costs that are not directly accountable to a particular function or product; these are fixed costs. Indirect costs include taxes, administration, personnel and security costs. See also
Changes in Financial Position Kobayashi Pharmaceutical Group's financial position in the third quarter of fiscal 2005 was as follows. Compared with the end of the previous fiscal year, total assets increased by 26,723 million yen but shareholder equity rose by only 5,416 million yen. As a result, shareholder equity ratio declined by 4.1 points. The principal increases were a 14,241 million yen gain in current assets Current Assets Appearing on a company's balance sheet, it represents cash, accounts receivable, inventory, marketable securities, prepaid expenses, and other assets that can be converted to cash within one year. (trade notes and accounts receivable accounts receivable n. the amounts of money due or owed to a business or professional by customers or clients. Generally, accounts receivable refers to the total amount due and is considered in calculating the value of a business or the business' problems in paying ) and 2,458 million yen in inventory assets due to consolidation of subsidiaries. Similarly, current liabilities Current Liabilities Usually appearing on a company's balance sheet, it represents the amount owed for interest, accounts payable, short-term loans, expenses incurred but unpaid, and other debts due within one year. (trade notes and accounts payable) increased by 16,363 million yen. Cash flows from operating activities Net cash provided by operating activities totaled 9,705 million yen. Although net income in the third quarter before tax and other adjustments was 12,370 million yen, corporate and other tax payments amounted to 5,971 million yen. Cash flows from investing activities Net cash used in investing operations totaled 4,940 million yen. This is mainly due to the acquisition of tangible fixed assets fixed assets npl → activo sg fijo fixed assets npl → immobilisations fpl fixed assets fix npl → for development of new products was 772 million yen and due to the acquisition of investments in securities through capital tie-ups. Cash flows from financing activities Net cash used in financing operations totaled 923 million yen. Capital outlays capital outlay See capital expenditure. included 1,373 million yen in dividends paid and 1,217 million yen for the acquisition of treasury stock, balanced through a third party investment in the Kobasho subsidiary. (4) Consolidated Projections for the FY ending March 31, 2005
------------------------------------------------------------------------
(Millions of Yen)
Net Sales 250,000
Ordinary Income 14,900
Net Income 7,100
Net Income per Share (yen) 169.52
------------------------------------------------------------------------
In the third quarter of fiscal 2005, results changed roughly in line with forecasts. Therefore, we have not revised the full-year earnings projections that we announced on May 17, 2005. *The projections shown above are prepared based on information available as of the issuing date of this report, and therefore the actual results may differ from the projected figures due to various unknown factors. About Kobayashi Pharmaceutical Kobayashi Pharmaceutical (TSE: 4967; OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : KBYPF) first opened for business in 1919, and management policy has always been to provide people and society with wonderful comfort through "Creativity and Innovation". Over the years the Company has expanded its scope, developing into a cluster of enterprises with three principal businesses: Consumer Products Operation, Wholesale Operation and Medical Devices Operation. In the fiscal year ended March 31, 2005, Kobayashi achieved increases in sales and profits for the seventh consecutive year since the introduction of consolidated accounting. Source: Kobayashi Pharmaceutical Contact: Kobayashi Pharmaceutical https://hint.kobayashi.co.jp/inq/inq0109.html Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion